Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States

BACKGROUND: Heart failure (HF) costs $21 billion annually in direct health care costs, 80% of which is directly attributable to hospitalizations. The SHIFT clinical study demonstrated that ivabradine plus standard of care (SoC) reduced HF-related and all-cause hospitalizations compared with SoC alon...

Descripción completa

Detalles Bibliográficos
Autores principales: Borer, Jeffrey S., Kansal, Anuraag R., Dorman, Emily D., Krotneva, Stanimira, Zheng, Ying, Patel, Harshali K., Tavazzi, Luigi, Komajda, Michel, Ford, Ian, Böhm, Michael, Kielhorn, Adrian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398043/
https://www.ncbi.nlm.nih.gov/pubmed/27579829
http://dx.doi.org/10.18553/jmcp.2016.22.9.1064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398043/
https://www.ncbi.nlm.nih.gov/pubmed/27579829
http://dx.doi.org/10.18553/jmcp.2016.22.9.1064

Ejemplares similares